Subscribe

Subscribe Today!

To sign up for our newsletter or print publications, please enter your contact information below.

I'd like to receive:

Enhertu First FDA-Approved Drug for HER2-Positive Non–Small-Cell Lung Cancer

JHOP - October 2022 Vol 12, No 5 - FDA Oncology Update
NEW INDICATIONS

On August 11, 2022, the FDA accelerated the approval of fam-trastuzumab deruxtecan-nxki (Enhertu; Daiichi Sankyo), an HER2-directed antibody and topoisomerase inhibitor conjugate, for the treatment of unresectable or metastatic non–small-cell lung cancer (NSCLC) in adults with HER2 mutations, as detected by an FDA-approved test, who have received systemic therapy. Fam-trastuzumab deruxtecan received a breakthrough therapy designation for this indication.

The FDA concomitantly approved the Oncomine Dx Target Test for tissue and the Guardant360 CDx plasma test as companion diagnostics for fam-trastuzumab deruxtecan: the tumor tissue test should be used if no mutation is detected with the plasma test.

Fam-trastuzumab deruxtecan was previously approved for several solid tumors involving the HER2 biomarker.

“After 2 decades of research into the role of targeting HER2 in lung cancer, the approval of the first HER2-directed treatment option validates HER2 as an actionable target in lung cancer,” said Bob T. Li, MD, PhD, MPH, Memorial Sloan Kettering Cancer Center.

This approval was based on the results of the multicenter, multicohort, randomized, blinded, dose-optimization DESTINY-Lung02 clinical trial of 52 patients with unresectable or metastatic HER2-positive nonsquamous NSCLC whose disease progressed after systemic therapy.

Patients received 5.4 mg of fam-trastuzumab deruxtecan intravenously every 3 weeks until unacceptable adverse events or disease progression. The objective response rate was 58% (95% confidence interval [CI], 43%-71%), and the duration of response was 8.7 months (95% CI, 7.1-not estimable).

The most common (≥20%) adverse events were nausea, decreased white blood cell count, decreased hemoglobin, decreased neutrophil count, decreased lymphocyte count, decreased platelet count, decreased albumin, increased aspartate aminotransferase, increased alanine aminotransferase, fatigue, constipation, decreased appetite, vomiting, increased alkaline phosphatase, and alopecia.

Related Items
Lytgobi FDA Approved for Intrahepatic Cholangiocarcinoma with FGFR2 Fusion
JHOP - October 2022 Vol 12, No 5 published on October 24, 2022 in FDA Oncology Update
Vegzelma a New Biosimilar FDA Approved for the Treatment of 6 Types of Cancer
JHOP - October 2022 Vol 12, No 5 published on October 24, 2022 in FDA Oncology Update
Pedmark First Drug Approved for Hearing Loss Prevention in Children with Solid Tumors
JHOP - October 2022 Vol 12, No 5 published on October 24, 2022 in FDA Oncology Update
Retevmo Receives New FDA Indication for Advanced Solid Tumors with RET Fusion
JHOP - October 2022 Vol 12, No 5 published on October 24, 2022 in FDA Oncology Update
Imfinzi Receives New FDA Indication for Advanced or Metastatic Biliary Tract Cancer
JHOP - October 2022 Vol 12, No 5 published on October 24, 2022 in FDA Oncology Update
Pemazyre Receives New Indication for FGFR1-­Positive Myeloid/Lymphoid Neoplasms
JHOP - October 2022 Vol 12, No 5 published on October 24, 2022 in FDA Oncology Update
Imbruvica Now Also Indicated for Children with Chronic Graft-versus-Host Disease
JHOP - October 2022 Vol 12, No 5 published on October 24, 2022 in FDA Oncology Update
Enhertu First FDA-Approved Treatment for HER2-Low Breast Cancer
JHOP - October 2022 Vol 12, No 5 published on October 24, 2022 in FDA Oncology Update
Nubeqa Now Indicated for Metastatic Hormone-Sensitive Prostate Cancer
JHOP - October 2022 Vol 12, No 5 published on October 24, 2022 in FDA Oncology Update
Xalkori Now FDA Approved for the Treatment of ALK-Positive Inflammatory Myofibroblastic Tumor
JHOP - August 2022 Vol 12, No 4 published on August 22, 2022 in FDA Oncology Update
Copyright © Green Hill Healthcare Communications, LLC. All rights reserved.